By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
In Senegal, these old provisions have been taken over by article L596 of Book V. Pharmaceutical industrial sector is dependent on foreign manufacturers, where 85% of the drug needs are imported.
In Senegal, where 85 to 90% of drug used are imported, difficulties are related to registration, competition of imported products, and especially the lack of regional purchasing power stations weigh on the local industries.
The GOS actively welcomes cooperation of U.S. companies in the health care sector, including in medical equipment, drone technology, eHealth solutions, and the development of facilities.
This sector is dominated by European products. Strong working relationships between the Centers for Disease Control and Prevention (CDC) and USAID’s Health Office and GOS counterparts can benefit U.S. firms by facilitating introductions.
Leading subsectors include X-Ray, scanning, and diagnostic equipment; eHealth systems and solutions; hospital and clinic development and equipment; pharmaceuticals; and innovative solutions such as drone delivery.
Opportunities exist to export specialized equipment. Several U.S.-based charities and development organizations donate refurbished medical equipment from the U.S. to Senegalese hospitals and medical practices for free.
In Senegal, despite the aforementioned increase in pharmacy number, the pharmaceutical sector is facing difficulties. According to statistics from private wholesalers, 40% of pharmacies are struggling, and 20 to 25 pharmacies closed each year.
However, apart from this situation, 228 licenses were issued in 6 years for the operation of pharmacies; a positive increase in the number of 21.11%. This growing trend over years shows that the pharmacy sector remains one of the most attractive areas of our profession.
Most countries in sub-Saharan Africa, including Senegal, have adopted a model of supplying drugs at no or low cost to their citizenry through a Central Medical Store and Essential Medicines List that aims to procure drugs at reduced cost and distribute them from the central to the local level, through a centralized planning and distribution process.
The Senegalese government is devoted to enhancing the population’s access to necessary medications.A number of programmes, such as price limits and subsidies for necessary medications, have been started to assure affordability and accessibility.
The government is developing a pharmaceutical industrial park that will provide infrastructure and support services to pharmaceutical companies.
Infectious diseases, problems with maternity and child health, and non-communicable diseases are just a few of the public health problems Senegal is dealing with.
In order to address these issues, the government has established a number of health programmes, including vaccination drives and disease control efforts.
In Senegal, there is a network of pharmacies and medical facilities that provide for the needs of the populace, making the distribution of pharmaceutical items well-organised. To guarantee that everyone has access to medicines, the pharmaceutical distribution system works with both the public and private sectors.
The Institut Pasteur de Dakar is building a new manufacturing plant that will produce vaccines and other essential medicines. This project is being supported by the European Union and other international partners.
The government is providing financial assistance to pharmaceutical companies to help them invest in research and development, production facilities, and marketing.
The Senegal pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Senegalese Government Approves New Pharmaceutical Manufacturing Facility:
In November 2023, the Senegalese government approved the construction of a new pharmaceutical manufacturing facility in Diamniadio. The facility, which is expected to begin production in 2025, will produce a range of essential medicines, including antibiotics, antiretrovirals, and antimalarials. This project is a significant step towards the government’s goal of increasing local production of pharmaceuticals.
Senegalese Government Launches Mobile App for Access to Medicine:
The Senegalese government has launched a new mobile app called “Allo Docteur” that allows patients to connect with doctors and pharmacists online. The app also provides information on pharmacies, drug prices, and health tips. This initiative is aimed at improving access to healthcare and medication for the Senegalese population.
GIZ Project Supports Development of Senegal’s Pharmaceutical Industry:
The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) is implementing a project to support the development of Senegal’s pharmaceutical industry. The project provides technical assistance to the government and private sector to help them improve the quality and safety of medicines, increase local production, and develop a sustainable pharmaceutical industry.
Johnson & Johnson Launches New HIV Prevention Medication: American multinational company Johnson & Johnson launched its new HIV prevention medication, Cabenuva, in Senegal in May 2023. Cabenuva is a long-acting injectable medication that provides protection against HIV for up to two months.
Pierre Fabre Launches New Anti-Fungal Medication: French pharmaceutical company Pierre Fabre launched its new anti-fungal medication, Luliconazole, in Senegal in March 2023. Luliconazole is a topical cream used to treat fungal skin infections.
Merck Launches New HIV Treatment Regimen: American pharmaceutical company Merck launched its new single-tablet regimen for HIV treatment, Pifeltro, in Senegal in September 2022. Pifeltro combines two antiretroviral drugs into a single tablet, making it easier for patients to adhere to their treatment regimen.
Sanofi Launches New Anti-Malarial Drug: French pharmaceutical giant Sanofi launched its new anti-malarial drug, Krintafel, in Senegal in July 2022. Krintafel is a long-acting injection intended for the treatment of uncomplicated Plasmodium falciparum malaria in adults and children aged six months and older. The drug received approval from the Senegalese Ministry of Health in June 2022.
